3 news items
Revolution Medicines Reports First Quarter 2024 Financial Results and Update on Corporate Progress
RVMD
8 May 24
or global pandemics. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated
Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
RVMD
9 Apr 24
of global events, such as international conflicts or pandemics. For a further description of the risks and uncertainties that could cause actual results
Revolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
RVMD
8 Apr 24
costs, and the effects on the company's business of global events, such as international conflicts or pandemics. For a further description of the risks
- Prev
- 1
- Next